SecurityGUAA / Guaranty Bancorp, Inc.
IndustryState Commercial Banks
Common Shares Outstanding29,308,857 shares (as of 2018-06-30)
Total Insiders24
Total Directors10
Total Officers12

Stock Insider Trading (from SEC Form 4)

Guaranty Bancorp, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GUAA / Guaranty Bancorp, Inc. insiders include TAYLOR PAUL W, O'Brien Patrick Dan, Apt Justin WYCOFF W KIRK, EGGEMEYER JOHN M III, BATCHELDER DAVID H, MCCONAHEY STEPHEN G, DiPetro Michael J, KLAPPER GAIL H, Pizzichini Anthony L., Miltimore Joseph E., and Noesen Michael J, Treece Christopher G, Joyce Stephen D, Erickson Christopher E, Finger Keith R., RELATIONAL INVESTORS LLC, Dickelman Keith, CORDES EDWARD B, BRENNAN SUZANNE R, WHITWORTH RALPH V, YATES ALBERT C, Hobbs Michael B, Goss Cathy P, .

Insider Roster

Insider Dir Off 10% Shares Owned
Joyce Stephen D Director
X 64,180
X 17,878
X 25,716
X 1,397,066
X 1,588,093
Finger Keith R. Director
X 75,241
X 3,196
X 42,995
O'Brien Patrick Dan EVP, Regional Pres., SBA Mgr.
X 27,052
Apt Justin Managing Principal
X 10,718
Erickson Christopher E EVP, Real Estate Banking
X 19,606
DiPetro Michael J EVP, Retail Banking Manager
X 3,419
Dickelman Keith EVP, Business Banking
X 25,512
TAYLOR PAUL W President & CEO, Director
X X 98,603
Pizzichini Anthony L. EVP, Regional President
X 25,581
Miltimore Joseph E. EVP, Middle Market
X 16,092
Noesen Michael J EVP, Credit Administration
X 44,219
Treece Christopher G EVP, CFO & Secretary
X 40,002
Hobbs Michael B President, Guaranty Bank
X 42,950
Goss Cathy P EVP & CCO
X 69,384
X 32,291

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-08-31 4 Joyce Stephen D P D 31.25 87 64,180 2,005,625
2018-05-25 4 Joyce Stephen D P D 33 82 64,093 2,115,059
2018-05-07 4 Joyce Stephen D A D 1,022 64,010
2018-05-07 4 CORDES EDWARD B A D 1,476 42,995
2018-05-07 4 BRENNAN SUZANNE R A D 1,022 3,196
2018-05-07 4 Finger Keith R. A D 1 75,241
2018-05-07 4 EGGEMEYER JOHN M III By Castle Creek Advisors IV LP A I 1,022 1,588,093
2018-05-07 4 WYCOFF W KIRK By Patriot Financial Manager, LP A I 1,022 1,397,066
2018-05-07 4 KLAPPER GAIL H A D 1,022 25,716
2018-05-07 4 MCCONAHEY STEPHEN G A D 1,022 17,878
2018-05-01 4 Apt Justin G D -36 10,718
2018-04-30 4 O'Brien Patrick Dan S D 28.65 -696 27,052 775,040
2018-04-27 4 O'Brien Patrick Dan S D 29 -820 27,748 804,692
2018-04-24 4 Erickson Christopher E S D 29.238 -680 19,606 573,240
2018-04-23 4 Dickelman Keith S D 29.40 -2,000 25,512 750,053
2018-04-23 4 DiPetro Michael J S D 29.40 -689 3,419 100,519
2018-04-13 4 TAYLOR PAUL W A D 1,640 98,603
2018-03-28 4 Erickson Christopher E F D 28.35 -320 20,286
2018-03-28 4 Noesen Michael J F D 28.35 -480 44,219
2018-03-28 4 DiPetro Michael J F D 28.35 -311 4,108
2018-03-28 4 Miltimore Joseph E. F D 28.35 -320 16,092
2018-03-28 4 O'Brien Patrick Dan F D 28.35 -480 28,568
2018-03-28 4 Pizzichini Anthony L. F D 28.35 -630 25,581
2018-03-16 4 O'Brien Patrick Dan S D 29.40 -696 29,048 854,011
2018-03-15 4 O'Brien Patrick Dan S D 29.30 -820 29,744 871,499
2018-03-13 4 Miltimore Joseph E. S D 29.26 -2,200 16,412 480,215
2018-03-08 4 Erickson Christopher E S D 28.9931 -2,589 20,606 597,432
2018-03-08 4 Noesen Michael J S D 28.8967 -7,500 24,699 713,720
2018-03-02 4 Joyce Stephen D P D 27.4565 96 62,988 1,729,441
2018-02-22 4 DiPetro Michael J S D 28.2959 -2,162 4,419 125,040
2018-02-12 4 O'Brien Patrick Dan A D 1,439 30,564
2018-02-12 4 O'Brien Patrick Dan M D 2,086 29,125
2018-02-12 4 O'Brien Patrick Dan F D 27.80 -688 27,039
2018-02-07 4 O'Brien Patrick Dan F D 27.75 -173 27,727
2018-02-05 4 O'Brien Patrick Dan F D 27.25 -519 27,900
2018-02-12 4 Apt Justin A D 1,799 10,754
2018-02-12 4 Apt Justin F D 27.80 -733 8,955
2018-02-12 4 Apt Justin M D 1,738 9,688
2018-02-07 4 Apt Justin F D 27.75 -318 7,950
2018-02-05 4 Apt Justin F D 27.25 -791 8,268
2018-02-12 4 Miltimore Joseph E. A D 1,349 18,612
2018-02-12 4 Miltimore Joseph E. M D 1,912 17,263
2018-02-12 4 Miltimore Joseph E. F D 27.80 -652 15,351
2018-02-07 4 Miltimore Joseph E. F D 27.75 -173 16,003
2018-02-05 4 Miltimore Joseph E. F D 27.25 -594 16,176
2018-02-12 4 Dickelman Keith A D 899 27,512
2018-02-12 4 Erickson Christopher E A D 1,529 23,195
2018-02-12 4 Erickson Christopher E M D 2,086 21,666
2018-02-12 4 Erickson Christopher E F D 27.80 -715 19,580
2018-02-07 4 Erickson Christopher E F D 27.75 -173 20,295
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

18h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

18h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

20h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Moody's (MCO) Concludes Acquisition of Omega Performance

2018-08-21 zacks
Moody’s Corporation (MCO - Free Report) recently completed the acquisition of Omega Performance, which was announced in July. The company made the acquisition with an objective to integrate Omega’s learning platform with its own services to provide clients with better solutions. Omega Performance, a business unit of TwentyEighty Inc, provides a variety of online credit training courses to at least 300 clients across the globe.

Zions' (ZION) Ratings Affirmed by Moody's, Outlook Positive

2018-08-08 zacks
Zions Bancorporation (ZION - Free Report) and its subsidiary’s ratings have been affirmed by Moody’s Investors Service, the rating arm of Moody’s Corporation (MCO - Free Report) . The outlook for the company has been upgraded to positive from stable. Zions’ senior unsecured rating has been affirmed at (P)Baa3. Its subsidiary’s Baseline Credit Assessment (BCA) stands at baa2 while its issuer rating has been affirmed at Baa3. (6-0)

Moody's to Buy Omega Performance to Enhance Credit Platform

2018-08-08 zacks
In an effort to enhance online credit training platform, Moody's Corporation (MCO - Free Report) has agreed to acquire Omega Performance, a business unit of TwentyEighty Inc. While the deal is expected to be completed within 30 days, it is not likely to have any material impact on Moody’s financials in 2018. Serving more than 300 customers, Omega Performance offers a wide range of online credit training courses. (6-0)

4 Reasons to Buy People's Utah Bancorp (PUB) Stock Right Now

2018-07-06 zacks
People's Utah Bancorp (PUB - Free Report) offers a profitable investment opportunity, driven by steady earnings growth and solid prospects. Also, easing margin pressure, supported by the improvement in the interest-rate scenario, is expected to aid top-line growth. The company is also witnessing upward estimate revisions, reflecting analysts’ optimism about its growth prospects. Over the last 60 days, the Zacks Consensus Estimate for 2018 has been raised nearly 1%. (1-0)

5 Reasons to Invest in East West Bancorp (EWBC) Stock Now

2018-06-22 zacks
East West Bancorp, Inc. (EWBC - Free Report) is well positioned for growth, supported by continued rise in loans and deposit balances, as well as increasing interest rates. Also, the company’s dividend payout policy seems impressive. Thus, it seems to be a wise idea to add the stock to your portfolio now. The company’s Zacks Consensus Estimate for the current-year earnings has been revised 3.1% upward over the last 60 days, reflecting analysts’ optimism regarding its earnings growth potential. (9-0)